> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# BMS Recalls 1 Lot of ‘Mislabeled’ Eliquis
- URL: https://www.fdaweb.com/bms-recalls-1-lot-of-mislabeled-eliquis/
- Published: 2017-06-13T12:00:00.000Z
- Updated: 2026-09-14T22:29:00.000Z
- Author: David McFarland
- Tags: Drugs, #legacy-id-D5138921

Bristol-Myers Squibb has recalled one lot (#HN0063) of its blood thinner Eliquis (apixaban) 5 mg tablets after a customer complaint said a bottle labeled as Eliquis 5 mg was found to contain Eliquis 2.5 mg tablets. “Patients who are prescribed Eliquis 5 mg for an irregular heartbeat (atrial fibrillation) and take an Eliquis 2.5 mg tablet instead, particularly for a prolonged period, would have an increased probability of stroke, a moving blood clot, or death,” according to a [recall notice](https://www.fda.gov/Safety/Recalls/ucm563002.htm?source=govdelivery&utm%5Fmedium=email&utm%5Fsource=govdelivery). “For patients with Deep Vein Thrombosis (DVT), a blood clot in one of the deep veins usually in the leg, and Pulmonary Embolism (PE), a blood clot in the lung, underdosing of the drug could lead to an increased risk of a growing or moving blood clot. Should that occur, it could be life-threatening or reversible depending on the severity and location of the blood clot. To date, there have not been any reports of injuries or illnesses related to this issue.”